ADVL0311 A PHASE I STUDY OF PEMETREXED (LY231514)

ADVL0311 培美曲塞 I 期研究 (LY231514)

• 批准号: 7376218
• 负责人: NITA L. SEIBEL
• 金额: $ 0.1万
• 依托单位: CHILDREN'S RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376218
• 关键词: ADVL0311; PHASE; STUDY; PEMETREXED; LY231514

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a phase I study of pemetrexed (LY231514, Alimta) in children and adolescents with recurrent solid tumors. Pemetrexed is a novel antifolate that inhibits multiple targets. Antimetabolites are cytotoxic drugs structurally similar to naturally occurring molecules necessary for the synthesis of pyrimidines, purines, and nucleic acids. Pemetrexed has anti-tumor activity through inhibition of several key folate-requiring enzymes, including thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyl transferase (GARFT). The study recommendation is to continue to accrue patients and to follow the escalation schema as specified. Once the MTD has been achieved, this agent should be moved forward to the phase II setting

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这是培美曲塞(LY231514，Alimta)在儿童和青少年复发性实体瘤中的I期研究。培美曲塞是一种新型的抗叶酸，可抑制多个靶点。抗代谢药物是一种结构类似于合成嘧啶、嘌呤和核酸所必需的天然分子的细胞毒性药物。培美曲塞通过抑制几种关键的叶酸合成酶(TS)、二氢叶酸还原酶(DHFR)和甘氨酰胺核苷酸甲酰转移酶(GARFT)而具有抗肿瘤活性。这项研究的建议是继续增加患者，并按照规定的升级方案进行。一旦达到MTD，应将该代理移至第二阶段设置